RUNX3 was found to be closely associated with the malignant transformation of EM (52, 54), with its expression level in Endometriomas being significantly higher than in Endometriosis, emphasizing its potential as a therapeutic target for EM. This evidence concerns the gene RUNX3 and erythema multiforme.